EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)

被引：0
|
作者：
Fenaux, P. [1 ]
Giagounidis, A. [2 ]
Selleslag, D. [3 ]
Knight, R. [4 ]
Fu, T. [4 ]
Hellstrom-Lindberg, E. [5 ]
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] St Johannes Hosp, Duisburg, Germany
[3] AZ St Jan Brugge AV, Brugge, Belgium
[4] Celgene Corp, Summit, NJ USA
[5] Karolinska Univ, Huddinge Hosp, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0311
引用
收藏
页码：125 / 125
页数：1
相关论文
共 44 条
  • [21] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 69 - 69
  • [22] A RANDOMISED STUDY OF LENALIDOMIDE (LEN) plus /- EPO IN RBC TRANSFUSION DEPENDENT (TD) IPSS LOW AND INT-1 (LOWER RISK) MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL 5Q RESISTANT TO EPO
    Toma, A.
    Chevret, S.
    Kosmider, O.
    Delaunay, J.
    Stamatoullas, A.
    Rose, C.
    Beyne-Rauzy, O.
    Banos, A.
    Guerci-Bresler, A.
    Jourdan, E.
    Sardnal, V.
    Caillot, D.
    Laribi, K.
    de Renzis, B.
    Bordessoule, D.
    Slama, B.
    Sanhes, L.
    Fontenay, M.
    Fenaux, P.
    Dreyfus, F.
    HAEMATOLOGICA, 2013, 98 : 454 - 455
  • [23] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Almeida, A.
    Giagounidis, A.
    Groepper, S.
    Jonasova, A.
    Vey, N.
    Mufti, G. J.
    Buckstein, R.
    Mittelman, M.
    Platzbecker, U.
    Shpilberg, O.
    Ram, R.
    del Canizo, C.
    Gattermann, N.
    Ozawa, K.
    Risueno, A.
    MacBeth, K. J.
    Zhong, J.
    Seguy, F.
    Hoenekopp, A.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
  • [24] Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q
    Fenaux, Pierre
    Guerci-Bresler, Agnes
    Muus, Petra
    Sekeres, Mikkael A.
    Giagounidis, Aristoteles
    Deeg, H. Joachim
    Greenberg, Peter
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS
    Almeida, A.
    Fenaux, P.
    Garcia-Manero, G.
    Giagounidis, A.
    Goldberg, S.
    Groepper, S.
    Jonasova, A.
    Mufti, G. J.
    Sanz, G. F.
    Vey, N.
    Castaneda, C.
    Zhong, J.
    Beach, C.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 502 - 502
  • [26] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stephanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Zhong, Jim
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    BLOOD, 2014, 124 (21)
  • [27] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [28] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [29] Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-l-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).
    Almeida, Antonio Medina
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Giagounidis, Aristoteles
    Goldberg, Stuart
    Gropper, Stefanie
    Jonasova, Anna
    Mufti, Ghulam J.
    Sanz, Guillermo F.
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to a Erythropoiesis-Stimulating Agent Who Are Lenalidomide- and HMA-Naive
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 12 - 13
12345